
Vivacitas Oncology: Innovating biopharmaceutical solutions for resistant cancers since 2015.
Vivacitas Oncology, founded in 2015 by Dr. Rubinfeld, is a biopharmaceutical company dedicated to combating cancers that are resistant to current treatment modalities. The company's core mission is to innovate and re-design well-known chemotherapies to enhance their efficacy against tough-to-treat cancers. Vivacitas Oncology focuses on developing advanced therapeutic solutions to address the unmet needs of cancer patients, aiming to improve survival rates and quality of life.
Notable affiliated individuals include co-founder Dr. Rubinfeld, who brings significant expertise to the company. Vivacitas Oncology has garnered attention for its strategic approach in re-engineering existing chemotherapies, contributing to advancements in oncology treatment. The company's impact is reflected in its commitment to addressing the challenges of resistant cancers, positioning itself as a key player in the biopharmaceutical industry focused on innovative cancer therapies.

Vivace Therapeutics

OnCusp Therapeutics
oncusptx.com

Novita Pharmaceuticals
novita-pharm.com

Cancervax
cancervax.com

Vanquish Oncology

OncoPrecision
oncoprecision.bio

MaveriX Oncology

OncoSpherix
oncospherix.com

Cullinan Oncology

Oncofactor
oncofactor.com

Curelab Oncology

OncoTartis

OncoResponse

NextCure
nextcure.com

Clovis Oncology
Companies similar to Vivacitas Oncology include Vivace Therapeutics, OnCusp Therapeutics, Novita Pharmaceuticals and Cancervax.
Vivacitas Oncology was founded in 2015.
Vivacitas Oncology's headquarters is located in Walnut Creek, CA, US.
Vivacitas Oncology's most recent funding round was for $100k (USD) in August 2021.
As of Aug 12, 2021, Vivacitas Oncology has raised a total of $100k (USD).
Vivacitas Oncology has 11 employees as of Feb 5, 2024.